S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$1.44
+3.6%
$1.36
$1.20
$7.13
$9.75M61.51558,077 shs243,985 shs
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
$0.02
+7.4%
$0.02
$0.01
$3.47
$1.14M1.57281,029 shs310,800 shs
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
$6.37
$0.38
$1.24
$26.05M0.91522,308 shs466,373 shs
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
$0.73
+5.8%
$0.66
$0.51
$0.99
$9.34M0.037,585 shs15,000 shs
PFHOD
Pacific Health Care Organization
$1.25
-69.5%
$1.25
$1.11
$5.90
$16M0.941,720 shs2,100 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
+3.60%+9.92%+2.86%-8.28%+143,999,900.00%
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
0.00%0.00%0.00%-20.44%-99.00%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00%0.00%0.00%0.00%0.00%
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
+5.80%+18.70%+16.24%+3.55%-16.09%
PFHOD
Pacific Health Care Organization
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
2.3344 of 5 stars
0.03.00.00.02.85.01.3
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
N/AN/AN/AN/AN/AN/AN/AN/A
PFHOD
Pacific Health Care Organization
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/A
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/A
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
N/AN/AN/AN/A
PFHOD
Pacific Health Care Organization
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$150K64.99N/AN/A$2.45 per share0.59
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
$1.27M0.90N/AN/A($14.93) per share0.00
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/A$1.54 per shareN/A
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
$5.63M1.66$0.05 per share15.17$0.88 per share0.83
PFHOD
Pacific Health Care Organization
$6.80M2.35$0.11 per share11.21$0.63 per share1.98

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$14.41M-$3.51N/AN/AN/A-9,873.97%-114.84%-107.19%5/10/2024 (Estimated)
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%5/10/2024 (Estimated)
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/A
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
$490K$0.0514.60N/A8.70%4.35%4.06%5/16/2024 (Estimated)
PFHOD
Pacific Health Care Organization
$1.36MN/A0.00N/A16.87%14.47%12.96%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/AN/A
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/AN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/A
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
N/AN/AN/AN/AN/A
PFHOD
Pacific Health Care Organization
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A
10.72
10.72
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/A
0.07
0.07
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/A
22.33
22.33
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
N/A
14.46
14.46
PFHOD
Pacific Health Care Organization
0.05
12.91
12.91

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
106.77 million5.31 millionNot Optionable
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
952.46 million52.41 millionNot Optionable
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
2760.58 million59.25 millionOptionable
Pacific Health Care Organization, Inc. stock logo
PFHO
Pacific Health Care Organization
3112.80 million4.92 millionNot Optionable
PFHOD
Pacific Health Care Organization
3912.80 millionN/ANot Optionable

CLBS, PFHOD, BXRX, PFHO, and BRTX Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioRestorative Therapies logo

BioRestorative Therapies

NASDAQ:BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Baudax Bio logo

Baudax Bio

NASDAQ:BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
Caladrius Biosciences logo

Caladrius Biosciences

NASDAQ:CLBS
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Pacific Health Care Organization logo

Pacific Health Care Organization

OTCMKTS:PFHO
Pacific Health Care Organization, Inc., together with its subsidiaries, operates as a specialty workers' compensation cost containment company in the United States. It is involved in managing and administering health care organizations (HCOs) and medical provider networks (MPNs). The company also provides claims-related services, including utilization review, medical case management, medical bill review, lien representation, workers' compensation carve-outs, expert witness testimony, and Medicare set-aside services. It serves self-administered employers, insurers, third-party administrators, municipalities, and others. The company was formerly known as Clear Air, Inc. and changed its name to Pacific Health Care Organization, Inc. in January 2001. Pacific Health Care Organization, Inc. was incorporated in 1970 and is based in Irvine, California.

Pacific Health Care Organization

OTCMKTS:PFHOD
Pacific Health Care Organization, Inc., together with its subsidiaries, provides specialty workers' compensation managed care services for self-administered employers, insurers, third party administrators, municipalities, and others in the United States. The company is involved in managing health care organizations (HCOs) and medical provider networks (MPNs); and negotiating legal agreements for the implementation of workers' compensation carve-outs for California clients/employers with collective bargaining units. It also offers HCO and MPN programs; medical case management services; and ancillary services, including utilization and medical bill review, lien representation, legal support, Medicare set aside, and network access services for workers' compensation claims. The company was formerly known as Clear Air, Inc. and changed its name to Pacific Health Care Organization, Inc. in January 2001. Pacific Health Care Organization, Inc. was incorporated in 1970 and is based in Newport Beach, California.